Patents by Inventor Fanny Norris
Fanny Norris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090011461Abstract: Human spasmolytic polypeptide (HSP) which has the amino acid sequence Glu Lys Pro Ser Pro Cys Gln Cys Ser Arg Leu Ser Pro His Asn Arg Thr Asn Cys Gly Phe Pro Gly Ile Thr Ser Asp Gln Cys Phe Asp Asn Gly Cys Cys Phe Asp Ser Ser Val Thr Gly Val Pro Trp Cys Phe His Pro Leu Pro Lys Gln Glu Ser Asp Gln Cys Val Met Glu Val Ser Asp Arg Arg Asn Cys Gly Tyr Pro Gly Ile Ser Pro Glu Glu Cys Ala Ser Arg Lys Cys Cys Phe Ser Asn Phe Ile Phe Glu Val Pro Trp Cys Phe Phe Pro Asn Ser Val Glu Asp Cys His Tyr or a functionally equivalent homologue thereof, characterized by being in glycosylated form.Type: ApplicationFiled: February 29, 2008Publication date: January 8, 2009Applicant: Novo Nordisk A/SInventors: Lars Thim, Kjeld Norris, Fanny Norris, Soren Erik Bjorn, Mogens Christensen, Per Franklin Nielsen
-
Publication number: 20080274964Abstract: Human spasmolytic polypeptide (HSP) which has the amino acid sequence Glu Lys Pro Ser Pro Cys Gln Cys Ser Arg Leu Ser Pro His Asn Arg Thr Asn Cys Gly Phe Pro Gly Ile Thr Ser Asp Gln Cys Phe Asp Asn Gly Cys Cys Phe Asp Ser Ser Val Thr Gly Val Pro Trp Cys Phe His Pro Leu Pro Lys Gln Glu Ser Asp Gln Cys Val Met Glu Val Ser Asp Arg Arg Asn Cys Gly Tyr Pro Gly Ile Ser Pro Glu Glu Cys Ala Ser Arg Lys Cys Cys Phe Ser Asn Phe Ile Phe Glu Val Pro Trp Cys Phe Phe Pro Asn Ser Val Glu Asp Cys His Tyr or a functionally equivalent homologue thereof, characterized by being in glycosylated form.Type: ApplicationFiled: February 29, 2008Publication date: November 6, 2008Applicant: NOVO NORDISK A/SInventors: Lars Thim, Kjeld Norris, Fanny Norris, Soren Erik Bjorn, Mogens Christensen, Per Franklin Nielsen
-
Publication number: 20060019881Abstract: Human spasmolytic polypeptide (HSP) which has the amino acid sequence Glu Lys Pro Ser Pro Cys Gln Cys Ser Arg Leu Ser Pro His Asn Arg Thr Asn Cys Gly Phe Pro Gly Ile Thr Ser Asp Gln Cys Phe Asp Asn Gly Cys Cys Phe Asp Ser Ser Val Thr Gly Val Pro Trp Cys Phe His Pro Leu Pro Lys Gln Glu Ser Asp Gln Cys Val Met Glu Val Ser Asp Arg Arg Asn Cys Gly Tyr Pro Gly Ile Ser Pro Glu Glu Cys Ala Ser Arg Lys Cys Cys Phe Ser Asn Phe Ile Phe Glu Val Pro Trp Cys Phe Phe Pro Asn Ser Val Glu Asp Cys His Tyr or a functionally equivalent homologue thereof, characterized by being in glycosylated form.Type: ApplicationFiled: July 19, 2005Publication date: January 26, 2006Inventors: Lars Thim, Kjeld Norris, Fanny Norris, Soren Bjorn, Mogens Christensen, Per Nielsen
-
Publication number: 20050287640Abstract: Human spasmolytic polypeptide (HSP) which has the amino acid sequence Glu Lys Pro Ser Pro Cys Gln Cys Ser Arg Leu Ser Pro His Asn Arg Thr Asn Cys Gly Phe Pro Gly Ile Thr Ser Asp Gln Cys Phe Asp Asn Gly Cys Cys Phe Asp Ser Ser Val Thr Gly Val Pro Trp Cys Phe His Pro Leu Pro Lys Gln Glu Ser Asp Gln Cys Val Met Glu Val Ser Asp Arg Arg Asn Cys Gly Tyr Pro Gly Ile Ser Pro Glu Glu Cys Ala Ser Arg Lys Cys Cys Phe Ser Asn Phe Ile Phe Glu Val Pro Trp Cys Phe Phe Pro Asn Ser Val Glu Asp Cys His Tyr or a functionally equivalent homologue thereof, characterized by being in glycosylated form.Type: ApplicationFiled: May 27, 2005Publication date: December 29, 2005Inventors: Lars Thim, Kjeld Norris, Fanny Norris, Soren Bjorn, Mogens Christensen, Per Nielsen
-
Patent number: 6908991Abstract: The present invention relates to mutations of a subtilisin gene which result in changes in the chemical characteristics of subtilisin enzymes. Mutations at specific nucleic acids of the subtilisin gene result in amino acid substitutions and consequently, altered enzyme function. Some of these mutant enzymes exhibit physical properties advantageous to industrial applications, particularly in the detergent industry, providing subtilisin which is more stable to oxidation, possesses greater protease activity, and exhibits improved washability.Type: GrantFiled: December 6, 2002Date of Patent: June 21, 2005Assignee: Novozymes A/SInventors: Sven Hastrup, Sven Branner, Fanny Norris, Steffen Bjorn Petersen, Leif Norskov-Lauridsen, Villy Johannes Jensen, Dorrit Aaslyng
-
Publication number: 20050003986Abstract: The present invention relates to mutations of a subtilisin gene which result in changes in the chemical characteristics of subtilisin enzymes. Mutations at specific nucleic acids of the subtilisin gene result in amino acid substitutions and consequently, altered enzyme function. Some of these mutant enzymes exhibit physical properties advantageous to industrial applications, particularly in the detergent industry, providing subtilisin which is more stable to oxidation, possesses greater protease activity, and exhibits improved washability.Type: ApplicationFiled: July 21, 2004Publication date: January 6, 2005Applicant: Novozymes A/SInventors: Sven Hastrup, Sven Branner, Fanny Norris, Steffen Petersen, Leif Norskov-Lauridsen, Villy Jensen, Dorrit Aaslyng
-
Patent number: 6835821Abstract: The present invention relates to mutations of a subtilisin gene which result in changes in the chemical characteristics of subtilisin enzymes. Mutations at specific nucleic acids of the subtilisin gene result in amino acid substitutions and consequently, altered enzyme function. Some of these mutant enzymes exhibit physical properties advantageous to industrial applications, particularly in the detergent industry, providing subtilisin which is more stable to oxidation, possesses greater protease activity, and exhibits improved washability.Type: GrantFiled: December 5, 2002Date of Patent: December 28, 2004Assignee: Novozymes A/SInventors: Sven Hastrup, Sven Branner, Fanny Norris, Steffen Bjorn Petersen, Leif Nørskov-Lauridsen, Villy Johannes Jensen, Dorrit Aaslyng
-
Patent number: 6808913Abstract: The present invention relates to mutations of a subtilisin gene which result in changes in the chemical characteristics of subtilisin enzymes. Mutations at specific nucleic acids of the subtilisin gene result in amino acid substitutions and consequently, altered enzyme function. Some of these mutant enzymes exhibit physical properties advantageous to industrial applications, particularly in the detergent industry, providing subtilisin which is more stable to oxidation, possesses greater protease activity, and exhibits improved washability.Type: GrantFiled: November 27, 2002Date of Patent: October 26, 2004Assignee: Novozymes A/SInventors: Sven Hastrup, Sven Branner, Fanny Norris, Steffen Bjørn Petersen, Leif Nørskov-Lauridsen, Villy Johannes Jensen, Dorrit Aaslyng
-
Publication number: 20030186378Abstract: The present invention relates to mutations of a subtilisin gene which result in changes in the chemical characteristics of subtilisin enzymes. Mutations at specific nucleic acids of the subtilisin gene result in amino acid substitutions and consequently, altered enzyme function. Some of these mutant enzymes exhibit physical properties advantageous to industrial applications, particularly in the detergent industry, providing subtilisin which is more stable to oxidation, possesses greater protease activity, and exhibits improved washability.Type: ApplicationFiled: December 5, 2002Publication date: October 2, 2003Applicant: Novozymes A/SInventors: Sven Hastrup, Sven Branner, Fanny Norris, Steffen Bjorn Petersen, Leif Norskov-Lauridsen, Villy Johannes Jensen, Dorrit Aaslyng
-
Publication number: 20030175933Abstract: The present invention relates to mutations of a subtilisin gene which result in changes in the chemical characteristics of subtilisin enzymes. Mutations at specific nucleic acids of the subtilisin gene result in amino acid substitutions and consequently, altered enzyme function. Some of these mutant enzymes exhibit physical properties advantageous to industrial applications, particularly in the detergent industry, providing subtilisin which is more stable to oxidation, possesses greater protease activity, and exhibits improved washability.Type: ApplicationFiled: December 6, 2002Publication date: September 18, 2003Applicant: Novozymes A/SInventors: Sven Hastrup, Sven Branner, Fanny Norris, Steffen Bjorn Petersen, Leif Norskov-Lauridsen, Villy Johannes Jensen, Dorrit Aaslyng
-
Publication number: 20030148495Abstract: The present invention relates to mutations of a subtilisin gene which result in changes in the chemical characteristics of subtilisin enzymes. Mutations at specific nucleic acids of the subtilisin gene result in amino acid substitutions and consequently, altered enzyme function. Some of these mutant enzymes exhibit physical properties advantageous to industrial applications, particularly in the detergent industry, providing subtilisin which is more stable to oxidation, possesses greater protease activity, and exhibits improved washability.Type: ApplicationFiled: November 27, 2002Publication date: August 7, 2003Applicant: Novozymes A/SInventors: Sven Hastrup, Sven Branner, Fanny Norris, Steffen Bjorn Petersen, Leif Norskov-Lauridsen, Villy Johannes Jensen, Dorrit Aaslyng
-
Publication number: 20030077696Abstract: A human spasmolytic polypeptide (HSP) having the amino acid SEQ ID NO:1, characterized by being in a glycosylated form.Type: ApplicationFiled: March 20, 2000Publication date: April 24, 2003Inventors: Lars Thim, Kjeld Norris, Fanny Norris, Soren Bjorn, Mogens Christensen, Per Franklin Nielsen
-
Patent number: 6506589Abstract: The present invention relates to mutations of the subtilisin gene, some of which result in changes in the chemical characteristics of subtilisin enzyme. Mutations are created at specific nucleic acids of the subtilisin gene and, in various specific embodiments, the mutant enzymes possess altered chemical properties including, but not limited to, increased stability to oxidation, augmented proteolytic activity, and improved washability. The present invention also relates, but is not limited to, the amino acid and DNA sequences for two proteases derived from Bacillus lentus variants, subtilisin 147 and subtilisin 309, as well as mutations of these genes and the corresponding mutant enzymes.Type: GrantFiled: June 7, 1995Date of Patent: January 14, 2003Assignee: Novozymes, A/SInventors: Sven Hastrup, Sven Branner, Fanny Norris, Steffen Bjørn Petersen, Leif Nørskov-Lauridsen, Villy Johannes Jensen, Dorrit Aaslyng
-
Patent number: 5783416Abstract: A human spasmolytic polypeptide (HSP) having the amino acid of SEQ ID NO:1, characterized by being in a glycosylated form.Type: GrantFiled: August 2, 1995Date of Patent: July 21, 1998Assignee: Novo Nordisk A/SInventors: Lars Thim, Kjeld Norris, Fanny Norris, S.o slashed.ren Erik Bj.o slashed.rn, Mogens Christensen, Per Franklin Nielsen
-
Patent number: 5741694Abstract: The present invention relates to mutations of the subtilisin gene, some of which result in changes in the chemical characteristics of subtilisin enzyme. Mutations are created at specific nucleic acids of the subtilisin gene and, in various specific embodiments, the mutant enzymes possess altered chemical properties including, but not limited to, increased stability to oxidation, augmented proteolytic activity, and improved washability. The present invention also relates, but is not limited to, the amino acid and DNA sequences for two proteases derived from Bacillus lentus variants, subtilisin 147 and subtilisin 309, as well as mutations of these genes and the corresponding mutant enzymes.Type: GrantFiled: June 7, 1995Date of Patent: April 21, 1998Assignee: Novo Nordisk A/SInventors: Sven Hastrup, Sven Branner, Fanny Norris, Steffen Bj.o slashed.rn Petersen, Leif N.o slashed.rskov-Lauridsen, Villy Johannes Jensen, Dorrit Aaslyng
-
Patent number: 5629176Abstract: A variant of the C-terminal Kunitz-type protease inhibitor domain of the .alpha.3 chain of human type VI collagen, the variant comprising the following amino acid sequence X.sup.1 X.sup.16 Asp Ile Cys Lys Leu Pro Lys Asp X.sup.2 Gly X.sup.3 Cys X.sup.4 X.sup.5 X.sup.6 X.sup.7 X.sup.8 X.sup.9 Trp Tyr Tyr Asp Pro Asn Thr Lys Ser Cys Ala Arg Phe X.sup.10 Tyr Gly Gly Cys X.sup.11 X.sup.12 X.sup.13 Glu Asn Lys Phe X.sup.14 Ser Gln Lys Glu Cys Glu Lys Val Cys Ala Pro X.sup.15 (SEQ ID NO. 1) wherein X.sup.1, X.sup.15, and X.sup.16 represents a naturally occurring amino acid residues except Cys and X.sup.2 -X.sup.14 each independently respresents a naturally occurring amino acid residue, with the proviso that at least one of the amino acid residues X.sup.1 -X.sup.16 is different from the corresponding amino acid residue of the native sequence. Alternatively, the N-terminal Asp may be preceded by H or 3-5 amino acid residues and the C-terminal Pro may be followed by OH or 3-5 amino acid residues.Type: GrantFiled: November 4, 1994Date of Patent: May 13, 1997Assignee: Novo Nordisk A/SInventors: S.o slashed.ren E. Bj.o slashed.rn, Kjeld Norris, Fanny Norris, Lars C. Petersen, Ole H. Olsen
-
Patent number: 5621074Abstract: The present invention relates to methods for producing aprotinin and analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aprotinin analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions comprising such analogs.Type: GrantFiled: May 18, 1995Date of Patent: April 15, 1997Assignee: Novo Nordisk A/SInventors: Soren E. Bj.o slashed.rn, Kjeld Norris, Viggo Diness, Leif N.o slashed.rskov-Lauritsen, Niels D. Christensen, Claus Bregengaard, Fanny Norris, Lars C. Petersen
-
Patent number: 5618696Abstract: The present invention relates to a human Kunitz-type protease inhibitor comprising the following amino acid sequenceAsp Leu Leu Pro Asn Val Cys Ala Phe Pro Met Glu Lys Gly Pro Cys Gln Thr Tyr Met Thr Arg Trp Phe Phe Asn Phe Glu Thr Gly Glu Cys Glu Leu Phe Ala Tyr Gly Gly Cys Gly Gly Asn Ser Asn Asn Phe Leu Arg Lys Glu Lys Cys Glu Lys Phe Cys Lys Phe Thr(SEQ ID NO:1)or a variant thereof with protease inhibitor properties.Type: GrantFiled: February 6, 1995Date of Patent: April 8, 1997Assignee: Novo Nordisk A/SInventors: Fanny Norris, Kjeld Norris, S.o slashed.ren E. Bj.o slashed.rn, Lars C. Petersen, Ole H. Olsen, Donald C. Foster, Cindy A. Sprecher
-
Patent number: 5618915Abstract: The present invention relates to methods for producing aprotinin and analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aprotinin analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions comprising such analogs.Type: GrantFiled: May 18, 1995Date of Patent: April 8, 1997Assignee: Novo NordiskInventors: Soren E. Bj.o slashed.rn, Kjeld Norris, Viggo Diness, Leif N.o slashed.rskov-Lauritsen, Niels D. Christensen, Claus Bregengaard, Fanny Norris, Lars C. Petersen
-
Patent number: 5591603Abstract: The present invention relates to methods for producing aprotinin and analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aprotinin analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions comprising such analogs.Type: GrantFiled: June 23, 1993Date of Patent: January 7, 1997Assignee: Novo Nordisk A/SInventors: Soren E. Bj.o slashed.rn, Kjeld Norris, Viggo Diness, Leif N.o slashed.rskov-Lauritsen, Niels D. Christensen, Claus Bregengaard, Fanny Norris, Lars C. Petersen